ArticlePloS one2024
Activity of glucose-6-phosphate dehydrogenease and its correlation with inflammatory factors in diabetic retinopathy.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Correlation risk analysis of serum inflammatory factors and 25-hydroxyvitamin D in vascular lesions in type 2 diabetes patients.Journal of medical biochemistry · 2026Article
- Metabolic reprogramming in diabetic complications: mechanisms, pathologies, and molecular evidence from multi-organ studies.Frontiers in immunology · 2026Review
- Article
- Bone-targeted mitochondrial delivery via magnetic-temperature responsive artificial cells for repairing age-related fractures.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to explore glucose-6-phosphate dehydrogenase (G6PD) activity in diabetic retinopathy (DR) and its correlation with inflammatory factors, elucidating the regulatory role of G6PD in DR pathology.
methodsA total of 151 T2DM patients were divided into three groups: diabetes without retinopathy (DNR, n = 59), non-proliferative retinopathy (NPDR, n = 46) and proliferative retinopathy (PDR, n = 49). Plasma G6PD activity was measured by a Randox G6PD kit and compared between these groups. Then the G6PD activity was correlated with inflammatory cytokines and metabolic parameters in these patients. A STZ-induced diabetic rat model was established, G6PD activity was validated by western blot and immunofluorescence staining in the retina of this model.
resultsPlasma G6PD activity decreased in the order of DNR, NPDR and PDR groups (P<0.01). G6PD activity was negatively correlated with IL-6, IL-8, TNF-α, cholesterol, and LDL (r = -0.1625, -0.1808, -0.1865, -0.1747, r = -0.1807, P<0.05). Multiple regression analysis showed TNF-α, IL-6, and LDL were independent related factors for G6PD. Logistic regression analysis showed G6PD, triglyceride, cholesterol, IL-8, TNF-α, and macular edema were influencing factors for T2DM with DR. Western Blot analysis indicated a significant reduction of G6PD expression in the retina, and immunofluorescence staining showed distribution of G6PD especially in the retinal endothelium cell decreased.
conclusionG6PD may play an important role in DR occurrence and progression, with decreased expression correlating closely with lipid metabolism and inflammatory factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.